A Phase-I Study of PDR001 Administered to Japanese Patients With Advanced Malignancies
Phase of Trial: Phase I
Latest Information Update: 15 Nov 2017
At a glance
- Drugs Spartalizumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Novartis Pharmaceuticals
- 07 Nov 2017 Status changed from active, no longer recruiting to completed.
- 30 Jun 2017 Planned End Date changed from 1 Jul 2017 to 18 Sep 2017.
- 30 Jun 2017 Planned primary completion date changed from 1 Jul 2017 to 18 Sep 2017.